secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004591
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm estimates FY2024 total rev ~$145M; Phase 3 MF data in 2H 2025
------------------------------------------------------------------------

- Preliminary FY2024 total revenue ~$145M, XPOVIO net product rev ~$113M; Q4 rev ~$30M, XPOVIO ~$29M.
- Phase 3 SENTRY trial (selinexor+ruxolitinib in MF) enrollment completion in 1H 2025, top-line data in 2H 2025.
- Appointed Lori Macomber as CFO (Jan 3, 2025) and Brendan Strong as SVP IR (Dec 9, 2024).
- Cash, equivalents, and investments ~$109M as of Dec 31, 2024; expected runway into Q1 2026 (excl. note repayment).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025004591/0000950170-25-004591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025004591/kpti-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer